Home   Chapter Home   Jobs   Conferences   Fellowships   Books



Advertisement

CD Markers

CD33


Reviewer: Charanjeet Singh, M.D., University of Minnesota (see Reviewers page)
Revised: 22 January 2011, last major update January 2011
Copyright: (c) 2002-2011, PathologyOutlines.com, Inc.

Definition
=========================================================================

● Classic myeloid antigen (also CD13)

Physiology
=========================================================================

● Glycosylated transmembrane protein of sialic acid-binding immunoglobulin-like lactic (siglec) family
● May mediate cell-to-cell adhesion; acts as receptor that inhibits the proliferation of normal and leukemic myeloid cells

Clinical features
=========================================================================

● Gemtuzumab ozogamicin (anti-CD33 antibody), was previously used to treat AML (Wikipedia, BioDrugs 2006;20:137, Cancer 2005;104:1442)
● Used for negative selection for stem cells

Uses
=========================================================================

● Distinguish myeloid (CD33+) and lymphoid leukemias (CD33-)
● Identify monocytes by flow cytometry

Positive stains - normal
=========================================================================

● Progenitor and other myeloid cells (decreasing expression with maturation, Am J Pathol 2001;158:1473)
● Basophils, granulocytes (low level expression), mast cells (Am J Pathol 1996;149:1493), monocytes (most), NK cells, plasmacytoid dendritic cells, T cells (some, J Leukoc Biol 2006;79:46)
● Epidermal Langerhans cells (variable)

Positive stains - disease
=========================================================================

● AML M0 (almost all, Am J Clin Pathol 2001;115:876), M1-M5 (75-85%), M7 (variable)
● ALK+ anaplastic large cell lymphoma (Am J Clin Pathol 2008;130:628), CML (90%), chronic myelomonocytic leukemia, myeloid / granulocytic sarcoma (J Clin Pathol 2005;58:325), transient myeloproliferative disorder (Am J Clin Pathol 2001;116:204)
● CD4+ CD56+ acute leukemias (Blood 2005;105:1256) and lineage negative malignancies (weak in 44%, Am J Surg Pathol 2005;29:1274)
● Myeloma and plasmacytoma (occasional reports)
● Burkitt’s lymphoma (J Clin Pathol 1993;46:778), SLL/CLL (Am J Clin Pathol 2003;119:824) or T-ALL (Am J Clin Pathol 2000;113:823)
● More intense in bone marrow than peripheral blood

Negative stains
=========================================================================

● Pluripotent stem cells, B cells
● Most B and T cell lymphomas, blastic NK lymphoma (usually)
● Not expressed outside hematopoietic system

Additional references
=========================================================================

OMIM 159590

End of CD Markers > CD33


This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).